BMS Beats Again Despite Eliquis and Cobenfy Disappointments

Why It Matters

The results highlight BMS’s ability to exceed revenue targets while exposing vulnerability in its flagship anticoagulant and emerging psychiatry portfolio, signaling strategic pressure on future growth.

Key Takeaways

• Q4 sales $12.5B beat $12.28B forecast.
• Eliquis revenue $3.4B, missed $3.71B expectations.
• Eliquis projected 10‑15% growth 2026, then decline 2027.
• Cobenfy sales $51M, 3% below consensus.
• BMS full‑year 2025 sales $48.2B beat estimates.

Pulse Analysis

Bristol Myers Squibb’s Q4 performance underscores the resilience of its diversified drug portfolio. By delivering $12.5 billion in sales, the company not only beat analyst forecasts but also reinforced its standing among the top pharmaceutical earners. The full‑year 2025 revenue of $48.2 billion, comfortably above consensus, reflects strong contributions from oncology, immunology, and cardiovascular segments, cushioning the impact of under‑performing products. Investors view this beat as a validation of BMS’s pricing strategy and cost‑control measures, especially as the industry navigates inflationary pressures and evolving payer dynamics.

Eliquis remains the linchpin of BMS’s cardiovascular franchise, yet its recent miss signals mounting headwinds. Although the drug posted $3.4 billion in Q4, it fell short of the $3.71 billion target, prompting skepticism about its growth trajectory. The company’s guidance of 10‑15 % sales expansion in 2026 hinges on the Inflation Reduction Act’s pricing reforms, which could lower out‑of‑pocket costs and sustain demand in the United States. However, the looming loss of exclusivity in Europe by late 2026 introduces a steep revenue cliff, as generic competition is expected to erode market share rapidly. Analysts are closely watching how BMS balances price concessions with volume growth to mitigate the projected $1.5‑$2 billion dip in 2027.

Cobenfy’s modest $51 million quarterly haul highlights the challenges of gaining traction in the crowded schizophrenia market. Despite near‑full coverage under Medicaid and Medicare and growing commercial acceptance, sales have yet to hit an inflection point. BMS is betting on a Phase 4 trial slated for later this quarter to demonstrate real‑world benefits and persuade clinicians to switch from traditional dopamine antagonists. If successful, the study could unlock broader adoption and improve the drug’s revenue profile, providing a counterbalance to the anticipated slowdown in Eliquis. Overall, BMS’s ability to convert pipeline momentum into sustainable sales will be pivotal for maintaining its growth outlook amid competitive pressures and patent expirations.